NCT05439408View on ClinicalTrials.gov

Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

June 25, 2021

Study Completion Date

June 25, 2021

Conditions
Biological Availability
Interventions
DRUG

Dasatinib ASD 100 mg

XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation

DRUG

Dasatinib 140 MG [Sprycel]

SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets

Trial Locations (1)

500037

QPS Bioserve India Pvt Limited, Hyderabad

All Listed Sponsors
collaborator

QPS Bioserve India Pvt Limited

UNKNOWN

lead

Xspray Pharma AB

INDUSTRY